Please login to the form below

Not currently logged in
Email:
Password:

idelalisib

This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.

EU clears AbbVie's leukaemia drug venetoclax

EU clears AbbVie's leukaemia drug venetoclax

have either failed chemoimmunotherapy or are unsuitable for treatment with a B-cell receptor pathway inhibitor such as AbbVie and Johnson &Johnson's Imbruvica (ibrutinib) or Gilead Science's Zydelig (idelalisib). ... had been previously treated with and

Latest news

More from news
Approximately 4 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

CES 2017 – Medical Device Top Picks
Connected tech was the overriding theme at this year's Consumer Electronics Show in Las Vegas. But among all that consumer gadgetry, there were some great medical devices too. So what...
Challenging times
It’s not an easy time for pharma, but there are opportunities for those companies that are willing to be true game changers...
The modern doctor is a digital nomad
How social networks have become the primary individual communication platforms for healthcare professionals...

Infographics